Acuvance
Acuvance combines healthcare M&A advisory with strategic, operational, valuation, clinical, technology, and compliance capabilities. The platform is backed by Trinity Hunt Partners and has publicly announced acquisitions of healthcare advisory and related professional-services firms.
What stands out about Acuvance
Acuvance presents publicly as a national healthcare advisory platform and strategic acquisition platform, rather than solely as a stand-alone financial intermediary. Its M&A Advisory practice supports strategic-alternative evaluation, value positioning, and transaction execution for healthcare organizations.[1][3][4][7][8]
What does Acuvance do?
Acuvance identifies itself as a national healthcare advisory platform uniting strategic, operational, financial, clinical, technology, and compliance capabilities. Its M&A Advisory practice guides healthcare organizations through strategic-alternative evaluation, value positioning, transaction execution, and other stages of the mergers-and-acquisitions lifecycle. The platform is publicly described as backed by Trinity Hunt Partners and built through the integration of specialized healthcare advisory firms.[1][4] Publicly stated transaction-related services include M&A Advisory, business valuation, and quality-of-earnings work. Announced platform acquisitions have added capabilities in clinical compliance and performance improvement, healthcare technology, analytics, revenue-cycle expertise, coding audit, health information management, and hospital ERP implementation and optimization.[1][3][5][6][7]Owners comparing advisory firms can also review Auxo’s M&A advisor vs. business broker vs. investment bank comparison, advisor-selection guide, and sell-side advisor evaluation framework.
What should a business owner evaluate before hiring Acuvance?
An owner evaluating Acuvance should clarify which legal entity would sign an acquisition agreement and how that entity relates to Acuvance, Coker, and Trinity Hunt Partners. The platform’s announced acquisitions and stated search for additional opportunities indicate an acquisition focus on healthcare advisory and related capabilities, but the official platform announcement does not state universal financial or transaction-size thresholds. Owners should also seek transaction-specific detail on valuation, consideration structure, integration expectations, leadership retention, branding, and autonomy. The ROI Healthcare Solutions announcement does not disclose purchase price, valuation, financing, consideration mix, or detailed transaction terms; the NorthGauge announcement states that transaction terms were not disclosed; and the TTG announcement does not disclose transaction terms, purchase price, valuation, financing, or consideration structure.[3][4][5][6][7][8]Which legal entity would sign an acquisition agreement, and how would that entity relate to Acuvance, Coker, and Trinity Hunt Partners
What healthcare subsectors, financial characteristics, geography, and owner objectives does Acuvance consider for additional acquisitions
How would valuation, quality of earnings, working capital, rollover equity, earn-outs, and other consideration components be handled in a particular transaction
What size transactions and clients does Acuvance focus on?
Acuvance states that it provides integrated solutions to hospitals, health systems, physician enterprises, and healthcare organizations nationwide. Its announced acquisition activity also references medical practices and surgery centers, including strategy, operations, financial, revenue-cycle, payer-strategy, and compliance services for those organizations.[2][8] Publicly announced acquisition examples include NorthGauge Healthcare Advisors on October 29, 2024; TTG Healthcare Advisors on October 31, 2024; Health Care Program Advisors on February 24, 2025; Healthcare Cost Solutions on June 25, 2025; and ROI Healthcare Solutions on January 20, 2026. The announcements describe added capabilities across clinical compliance, performance improvement, medical-practice and surgery-center services, healthcare technology and analytics, revenue cycle, coding and health information management, and hospital ERP implementation and optimization.[3][5][6][7][8] Acuvance publicly offers M&A Advisory covering strategic-alternative evaluation, positioning for value, and transaction execution. Its public platform activity also includes acquisitions of healthcare advisory and related professional-services firms, with the platform stating that it was seeking additional acquisition opportunities and partnerships with healthcare advisory firms in the United States.[1][4]What does Acuvance publicly disclose about fees, process and engagement terms?
The official Acuvance M&A Advisory page does not publish a universal engagement-fee percentage, minimum fee, tail period, termination schedule, or standard exclusivity terms. The official platform announcement does not state a universal minimum revenue, EBITDA, enterprise-value, or transaction-size threshold for additional acquisition opportunities. The official ROI Healthcare Solutions acquisition announcement identifies the acquisition and strategic rationale but does not disclose purchase price, valuation, financing, consideration mix, or detailed transaction terms. The official NorthGauge acquisition announcement states that the transaction terms were not disclosed, while the official TTG announcement does not disclose transaction terms, purchase price, valuation, financing, or consideration structure.[1][3][4][7][8] Acuvance is publicly described as a healthcare advisory platform backed by Trinity Hunt Partners and assembled through the integration of specialized healthcare advisory firms. The public description establishes the platform and parent context; it does not, by itself, specify the legal entity that would sign a particular advisory engagement or acquisition agreement.[4] Acuvance states that its M&A Advisory team supports healthcare organizations through the mergers-and-acquisitions lifecycle, including strategic-alternative evaluation, value positioning, and transaction execution. In its September 23, 2025 platform announcement, Acuvance stated that it was actively seeking additional acquisition opportunities and partnerships with healthcare advisory firms in the United States.[1][4]Questions to ask before hiring Acuvance
Which legal entity would sign an acquisition agreement, and how would that entity relate to Acuvance, Coker, and Trinity Hunt Partners?
What healthcare subsectors, financial characteristics, geography, and owner objectives does Acuvance consider for additional acquisitions?
How would valuation, quality of earnings, working capital, rollover equity, earn-outs, and other consideration components be handled in a particular transaction?
What integration, branding, leadership-retention, and operating-autonomy expectations would apply to a seller?
For a sell-side advisory engagement, what are the fee mechanics, minimum fee, expense treatment, exclusivity, termination, and tail provisions?
Sources & research notes
- Official website / firm overview
- Industry / market focus
- Geography / market coverage
- Structure / regulatory context
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.